Drug Trial Radar · NCT05186506
A Study Comparing Ensatinib Versus Platinum-Based Chemotherapy as Adjuvant Treatment for Stage II-IIIA ALK -Positive Non-Small Cell Lung Cancer
Last checked: Nov 20, 2026Latest source record: Jan 11, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
152
Planned (sponsor's estimate)
Start
Jan 1, 2022
Primary completion
Dec 15, 2025
Study completion Dec 20, 2028
Sponsor
- Lead sponsor
- Sichuan UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Betta Pharmaceuticals Co., Ltd.
- First posted
- Jan 11, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 73 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This randomized, active-controlled, multicenter, open-label, Phase II study is designed to evaluate the efficacy and safety of ensatinib compared with Platinum-Based Chemotherapy as adjuvant treatment in ALK fusion positive II-IIIA stage non-small cell lung cancer after surgical resection
Conditions
- ALK Fusion Protein Expression
- Adjuvant Therapy
- Non-Small Cell Lung Cancer
Interventions
EnsatinibDrug
225 mg administered once daily orally for two years.
chemotherapyDrug
Pemetrexed : Participants will receive 500 mg/m\^2, day 1 , Q21D , until completion of treatment period (4 cycles), recurrence of disease, unacceptable toxicity, withdrawal of consent, or death, whichever occurs first. Cisplatin :Participants will receive 75 mg/m\^2, day 1 , 21 days/cycle, Q21D , until completion of treatment period (4 cycles), recurrence of disease, unacceptable toxicity, withdrawal of consent, or death, whichever occurs first. Paclitaxel: Participants will receive 175 mg/ m\^2, day 1 , 21 days/cycle, Q21D , until completion of treatment period (4 cycles), recurrence of disease, unacceptable toxicity, withdrawal of consent, or death, whichever occurs first. carboplatin AUC= 5 mg/ mL/min, intravenously guttae, day 1 ,Q21D ,until completion of treatment period (4 cycles), recurrence of disease, unacceptable toxicity, withdrawal of consent, or death, whichever occurs first.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Disease free survival (DFS)Time frame: From date of randomization until date of the first observation of tumor recurrence, metastasis (based on imaging ) or death, up to approximately 5 years.
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.